Results 171 to 180 of about 10,961,826 (306)

Associations of serum CA 15-3 with interstitial lung disease, PM/Scl100 antibodies and other disease characteristics in systemic sclerosis. [PDF]

Sci Rep
Trefler J, Pasierb A, Lech L, Życińska K.   +3 more
europepmc   +1 more source

Disposable electrochemical detection of breast cancer tumour marker CA 15-3 using poly(Toluidine Blue) as imprinted polymer receptor.

Biosensors & bioelectronics, 2018
J. A. Ribeiro, C. Pereira, A. F. Silva, M. Sales   +3 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Cáncer de mama en una paciente de 21 años

Medisan
Se presenta el caso clínico de una paciente de 21 años de edad, quien acudió a la consulta de Oncología del Hospital Gubernamental de Mbabane en Suazilandia por presentar un nódulo en la mama derecha con manifestaciones de dolor intenso desde hacía 1 mes.
Ernesto Arias Beatón, Martha Beatriz Arias Beatón, Yoryana Elena Tellería León, Yosvanis Causa Torres   +3 more
doaj  

Falsely Elevated CA 15-3 Levels in Ovarian Sarcoidosis with Peritoneal Involvement and Ascites. [PDF]

Case Rep Obstet Gynecol, 2018
Tsiodras S, Gouloumi AR, Tsakiraki Z, Chrelias G, Chrelias C, Loukides S, Panayiotides I.   +6 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery. [PDF]

Ecancermedicalscience, 2019
Buonomo B, Noli SA, Santini A, Alviggi C, Peccatori FA.   +4 more
europepmc   +1 more source

CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.

Anticancer Research, 2018
Š. Svobodová, R. Kučera, O. Fiala, M. Karlíková, A. Narsanska, I. Zedníková, V. Treska, D. Slouka, M. Roušarová, O. Topolcan, J. Finek   +10 more
semanticscholar   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Prevalence of CEA, CA 125, and CA 15-3 serum tumour markers in different regions of Saudi Arabia. [PDF]

Saudi Med J
Ashi A, Al-Hajeili M, Almaghrabi S, Al-Maghrabi J, Trabulsi N, Alghuraibi S, Alsiary R, Alrayes N.   +7 more
europepmc   +1 more source